Cholesterol-lowering Drug Market Analysis Report by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Others) and Disease Type (Hypercholesterolemia, Cardiovascular Diseases, and Hyperlipidemia): Global Opportunity Analysis and Industry Forecast, 2019–2026

Pharmaceuticals	LI_195509	Pages: NA	Dec 2019 \| 203 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Cholesterol is an organic molecule that belongs to the group of steroids and is a type of lipid. It is biosynthesized by all animal cells, and is an essential structural component of animal cell membranes. The significance of cholesterol is the biosynthesis of steroid hormones such as estrogen and testosterone, as well as bile acid and vitamin D. About 80% of cholesterol production occurs in liver and intestines, and the rest comes from dietary sources such as meat, poultry, eggs, fish, and dairy products. Although cholesterol is fundamentally required by the body, more than 240 mg/dl is considered as high cholesterol. A total cholesterol of 200 mg/dl or lower is acceptable, and 200–240 mg/dl is considered borderline high. This elevated level of cholesterol in the blood is termed as hypercholesterolemia. High cholesterol may be a consequence of unhealthy diet, obesity, genetic diseases, or other diseases such as type 2 diabetes and an underactive thyroid.

The global cholesterol lowering drug market is anticipated to grow modestly during the forecast period. Some of the factors anticipated to boost the cholesterol lowering drug market growth are emergence of new drug classes, changes in lifestyles, lack of exercise, and increase in intake of saturated & trans-fat. In addition, increase in smoking and alcohol consumption escalate the risk of high cholesterol, thus driving the market growth. However, severe side effects of statins causing rhabdomyolysis and availability of generic drugs of leading brands are projected to restrain the market growth during the forecast period. On the contrary, lucrative opportunities in emerging economies are expected to provide significant prospects for the manufacturers in industry.

Emergence of more effective therapies such as PCSK9 inhibitors, bempedoic acid, and the upcoming drug by The Medicines Company, inclisiran is anticipated to expand the range of clinical indications. Inclisiran is an upcoming drug, which may enter the market by 2020, and is expected to become the third potent drug after the two PCSK9 inhibitors, Repatha (Amgen) and Praluent (Sanofi/Regeneron). Former CEO of the Medicines Company, Dr. Clive Meanwell indicated that the company is likely to keep cost lower than that of PCSK9 inhibitors to bring the medicine to the masses. Furthermore, inclisiran has significant advantage over the two, for its requirement of only 2 dose per year. For comparison, PCSK9 needs to be dosed every two weeks.

This report segments the cholesterol-lowering drug market based on drug class, disease type, and region. Depending on drug class, the market can be classified as statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and others. By disease type, it categorized into hypercholesterolemia, cardiovascular diseases, and hyperlipidemia. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The report provides a comprehensive analysis of the key players operating in the global cholesterol lowering drug market players such as AstraZeneca, Merck & Co., Pfizer Inc., Kowa Company, Daiichi Sankyo Company, Limited, AbbVie Inc., Novartis AG, Sanofi S.A., Amgen Inc., and Bristol-Myers Squibb (BMS). The other players in the value chain includes Covis Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Bausch Health Companies Inc., Aegerion Pharmaceuticals, Aralez Pharmaceuticals, and others.

KEY BENEFITS FOR STAKEHOLDERS

An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global cholesterol lowering drugs market is provided.
Region-wise and country-wise market conditions are comprehensively analyzed in this report.
The projections in this report are made by analyzing the current trends and future market potential from 2019 to 2026 in terms of value.
An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
Key market players within the cholesterol lowering drugs market are profiled in this report, and their strategies are analyzed thoroughly, which helps to understand the competitive outlook of global cholesterol lowering drugs market.

KEY MARKET SEGMENTS

By Drug Class

Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Others

By Disease Type

Hypercholesterolemia
Cardiovascular Diseases
Hyperlipidemia

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,110 Data Pack/Excel ~~$3,840~~ $3,456 Single User License ~~$5,370~~ $4,833 Five User License ~~$6,450~~ $5,805 Enterprise User License ~~$8,995~~ $8,096

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com